U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07549321) titled 'A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients' on April 09.
Brief Summary: Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years. Most patients have 'high-risk' disease, with spread of the disease to different sites (metastases). This multinational study aims to find out how effective and safe the treatment of a monoclonal anti-GD2 antibody hu14.18K322A (daretabart) is when used together with chemotherapy to treat children and young people who have hig...